Merck's Zaire Ebolavirus Vaccine Registered in Four African Countries
14 Febbraio 2020 - 6:43PM
Dow Jones News
By Stephen Nakrosis
Merck & Co. Inc. said Friday its Ervebo vaccine, which is
indicated for the prevention of disease caused by Zaire ebolavirus,
was approved in four African countries.
Merck said the vaccine was registered in the Democratic Republic
of the Congo, Burundi, Ghana and Zambia.
Merck had previously said it is working to begin manufacturing
licensed doses and expects them to be available staring around the
third quarter of 2020. Merck is working with the U.S. government,
WHO, UNICEF, and others to plan for how "licensed doses will
support future public health preparedness and response efforts
against Zaire ebolavirus disease."
Ervebo doesn't protect against other species of Ebolavirus or
Marburgvirus, Merck said.
The vaccine "was granted a conditional marketing authorization
by the European Commission on November 11, 2019 and approved by the
U.S. Food and Drug Administration on Dec. 20, 2019," the company
said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 14, 2020 12:28 ET (17:28 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Merck (NYSE:MRK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Merck (NYSE:MRK)
Storico
Da Apr 2023 a Apr 2024